Laura Johnston

2.1k total citations
28 papers, 372 citations indexed

About

Laura Johnston is a scholar working on Hematology, Surgery and Oncology. According to data from OpenAlex, Laura Johnston has authored 28 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 11 papers in Surgery and 9 papers in Oncology. Recurrent topics in Laura Johnston's work include Hematopoietic Stem Cell Transplantation (12 papers), Transplantation: Methods and Outcomes (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). Laura Johnston is often cited by papers focused on Hematopoietic Stem Cell Transplantation (12 papers), Transplantation: Methods and Outcomes (10 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers). Laura Johnston collaborates with scholars based in United States, Australia and Germany. Laura Johnston's co-authors include Amy E Lingard, Wibke Stansen, Richard Malík, Scott A. Brown, Judith A. Shizuru, Robert S. Negrin, Keith Stockerl‐Goldstein, C. Kusnierz-Glaz, Randolph M. Baral and Ruby M. Wong and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Laura Johnston

20 papers receiving 354 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Johnston United States	12	140	107	85	73	71	28	372
Marilyn E. Dunn Canada	10	46 0.3×	101 0.9×	58 0.7×	84 1.2×	13 0.2×	19	295
Tamara B. Wills United States	10	53 0.4×	62 0.6×	36 0.4×	96 1.3×	17 0.2×	18	290
Barbara Voss United States	14	14 0.1×	13 0.1×	265 3.1×	48 0.7×	62 0.9×	17	571
E. Martín Spain	10	18 0.1×	32 0.3×	95 1.1×	22 0.3×	6 0.1×	38	384
Fatih Erbey Türkiye	10	76 0.5×	14 0.1×	38 0.4×	30 0.4×	45 0.6×	42	338
Paola Muggeo Italy	12	32 0.2×	9 0.1×	57 0.7×	50 0.7×	61 0.9×	40	382
L. Leduc Canada	10	117 0.8×	4 0.0×	48 0.6×	31 0.4×	15 0.2×	30	664
Konstantinos Argyriou Greece	8	29 0.2×	11 0.1×	85 1.0×	49 0.7×	52 0.7×	28	267
Romanos Haykal United States	4	17 0.1×	6 0.1×	56 0.7×	42 0.6×	16 0.2×	13	390
Roswell W. Phillips United States	13	28 0.2×	31 0.3×	52 0.6×	94 1.3×	47 0.7×	25	378

Countries citing papers authored by Laura Johnston

Since Specialization

Citations

This map shows the geographic impact of Laura Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Johnston more than expected).

Fields of papers citing papers by Laura Johnston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Johnston. The network helps show where Laura Johnston may publish in the future.

Co-authorship network of co-authors of Laura Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Johnston. A scholar is included among the top collaborators of Laura Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Johnston. Laura Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharifi, Husham, Christian O’Donnell, Laura Johnston, et al.. (2025). Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease. Blood Advances. 9(19). 5024–5037.

Sharifi, Husham, Charlotte Moss, Christian O’Donnell, et al.. (2025). Pirfenidone for the Treatment of Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplant: Results from a Single-Arm Extension Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1133–A1133. 1 indexed citations

Epstein, David J., Husham Sharifi, H. Henry Guo, et al.. (2025). Bronchiectasis in Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 31(11). 922.e1–922.e12.

Kennedy, Vanessa E., Parveen Shiraz, Sally Arai, et al.. (2025). Comparison of Post-Transplant Cyclophosphamide Vs Methotrexate and Calcineurin Inhibitor for Gvhd Prophylaxis in Myeloablative Transplants with HLA Matched Donors. Transplantation and Cellular Therapy. 31(2). S304–S304.

Sharifi, Husham, Christian O’Donnell, Clark G. Owyang, et al.. (2022). The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplantation. 57(8). 1319–1326. 13 indexed citations

Johnston, Laura, et al.. (2022). Carol's journey in critical care: An Enlighten Project case study. Trends in Anaesthesia and Critical Care. 44. 3–7.

Muffly, Lori, Parveen Shiraz, Judith A. Shizuru, et al.. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy. 27(7). 590.e1–590.e8. 12 indexed citations

Chazot, Paul L., et al.. (2019). Histamine and Delirium: Current Opinion. Frontiers in Pharmacology. 10. 299–299. 15 indexed citations

Hawkes, Eliza A., Jodie Palmer, Michael MacManus, et al.. (2019). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. Blood. 134(Supplement_1). 5328–5328. 1 indexed citations

10.

Gooptu, Mahasweta, Haesook T. Kim, Yi‐Bin Chen, et al.. (2018). Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biology of Blood and Marrow Transplantation. 24(11). 2216–2223. 20 indexed citations

11.

Srinivas, Sandhya, et al.. (2017). Epidemiology and Burden of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections in Bone Marrow Transplant and Hematology-Oncology Units. American Journal of Infection Control. 45(6). S38–S38.

12.

Johnston, Laura, et al.. (2017). Integrating cancer survivorship care into allogeneic BMT recovery.. Journal of Clinical Oncology. 35(5_suppl). 39–39. 1 indexed citations

13.

Cheng, Guang‐Shing, Barry E. Storer, Jason W. Chien, et al.. (2016). Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. Annals of the American Thoracic Society. 13(11). 1932–1939. 49 indexed citations

14.

Carpenter, Paul A., Brent R. Logan, Stephanie J. Lee, et al.. (2016). Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation. 22(3). S50–S52. 3 indexed citations

15.

Tierney, D. Kathryn, Oxana Palesh, & Laura Johnston. (2015). Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation. Oncology nursing forum. 42(5). 488–497. 13 indexed citations

16.

Williams, Kirsten M., Guang‐Shing Cheng, Iskra Pusic, et al.. (2015). Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 21(2). S61–S62. 1 indexed citations

17.

Cheng, Guang‐Shing, Iskra Pusic, Madan Jagasia, et al.. (2015). BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial. Biology of Blood and Marrow Transplantation. 21(2). S172–S173.

18.

Naik, Seema, Robert J. Wong, Sally Arai, et al.. (2010). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplantation. 46(2). 192–199. 7 indexed citations

19.

Gravel, Denise, et al.. (2002). CANADIAN HOSPITAL EPIDEMIOLOGY COMMITTEE. CANADIAN NOSOCOMIAL INFECTION SURVEILLANCE PROGRAM. PROSPECTIVE SURVEILLANCE FOR PRIMARY BLOODSTREAM INFECTIONS OCCURRING IN CANADIAN HEMODIALYSIS UNITS. 23(12). 716–720. 7 indexed citations

20.

Kusnierz-Glaz, C., Robert S. Negrin, Judith A. Shizuru, et al.. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of Blood and Marrow Transplantation. 5(5). 299–305. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact